In the latest analyst update, HC Wainwright & Co. has maintained its "Buy" rating for TScan Therapeutics (TCRX, Financial), though it has lowered the price target from $15.00 to $10.00 USD. This change represents a 33.33% decrease in the price target.
The analyst responsible for this revision is Andres Maldonado, who continues to express confidence in TScan Therapeutics (TCRX, Financial) by maintaining the "Buy" rating despite the adjustment in expectations. The update was released on May 7, 2025, with the company's stock listed on the NASDAQ exchange.
Investors should note that the lowered price target may influence market perceptions and stock performance, but the continued "Buy" rating indicates ongoing positive sentiment from HC Wainwright & Co. analyst Andres Maldonado towards TScan Therapeutics (TCRX, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for TScan Therapeutics Inc (TCRX, Financial) is $9.00 with a high estimate of $12.00 and a low estimate of $3.00. The average target implies an upside of 561.76% from the current price of $1.36. More detailed estimate data can be found on the TScan Therapeutics Inc (TCRX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, TScan Therapeutics Inc's (TCRX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for TScan Therapeutics Inc (TCRX, Financial) in one year is $0.14, suggesting a downside of 89.71% from the current price of $1.36. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the TScan Therapeutics Inc (TCRX) Summary page.
